FDA panel backs ICS/LABA inhaler for COPDMechcatie, Elizabeth
Combination ICS/fast-onset LABA inhaler as maintenance and reliever therapy: the future for uncontrolled adult asthma? Expert Rev Respir Med 2013;7:451-4.Patel M, Pilcher J, Beasley R. Combination ICS/fast‑onset LABA inhaler as maintenance and reliever therapy: The future for ...
In this post-hoc analysis of data from three large 1-year studies, single-inhaler triple therapy with BDP/FF/G delayed COPD deterioration compared with ICS/LABA and LAMA monotherapy, both for time to first CID and time to sustained CID, and delayed the time to first CID compared with LABA...
Baseline characteristics for asthma and non-asthma par- ticipants are shown in Table 1. All asthma participants were prescribed maintenance ICS/LABA inhaler therapy with a mean daily dose of 489 µg/day of fluticasone pro- pionate (FP) or equivalent as the ICS component. The Caswell...
There are concerns regarding long-term complications (weight gain, osteoporosis, cataract) and increased risk of community-acquired pneumonia with the use of inhaled corticosteroids (ICS). The new LAMA/LABA inhalers could potentially reduce the use of ICS as part and parcel of maintenance therapy ...
An alternative to combination ICS/albuterol reliever treatment is the use of separate ICS and SABA inhalers at the same time as reliever therapy. There is an evidence base for the efficacy and safety of this approach in both children and adults; however, there is a major practical limitation ...
CichowiczDepartment of Chemistry and Biochemistry La Salle UniversityJamil Kh. Dierov... MJ Haas,DJ Cichowicz,JK Dierov - 《Journal of the American Oil Chemists Society》 被引量: 13发表: 2001年 Add-on LABA in a separate inhaler as asthma step-up therapy versus increased dose of ICS or...
Tariq SM, Thomas EC. Maintenance therapy in COPD: time to phase out ICS and switch to the new LAMA/LABA inhalers? Int J Chron Obstruct Pulmon Dis. 2017;12:1877-1882.Tariq SM, Thomas EC. Maintenance therapy in COPD: time to phase out ICS and switch to the new LAM...
Advisory panel backs ICS/LABA inhaler for COPD.(NEWS FROM THE FDA)(chronic obstructive pulmonary disease)(inhaled corticosteroid/long-acting beta-2 agonist)Mechcatie, Elizabeth
concomitant ICS therapy or scheduled medical review, that there is no evidence of an increased risk of asthma mortality with combination ICS/LABA inhaler therapy in asthma, and that it is only with combination ICS/LABA products that it could be guaranteed that LABA monother-apy can be avoided....